---
title: "Four device certificates and 80 people, behind a nearly 100-million-yuan round"
date: 2026-11-20
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-bsi-pre-a-1120
language: en
---

# Four device certificates and 80 people, behind a nearly 100-million-yuan round

> Suzhou Ruiyi Xulian raised close to 100 million yuan for a brain-spine interface, with four device certificates, 80 staff and two cases each in paralysis and stroke.

On November 19, Suzhou Ruiyi Xulian Medical Technology announced it had raised close to 100 million yuan in a Pre-A+ round.

Economic Observer reported that Puhua Capital and Furon Investment co-led, with Songhe Capital and Beijing Industrial Development Investment participating. Xingqiao Capital served as exclusive financial adviser for follow-on financing.

The money has three destinations: push the core brain-spine interface product into clinical trials, support volume production of a modular implantable bidirectional platform, and extend indications into language decoding, visual reconstruction and depression.

## What a brain-spine interface bypasses

In a spinal cord injury, the brain still issues commands. The pathway down the cord is what breaks.

The brain-spine approach reads movement intent from the brain, decodes it, and stimulates the spinal cord below the injury so muscles receive a signal again.

That is different from recording cortical signals alone. It requires three things at once: implantable acquisition, real-time decoding, and spinal stimulation.

Zhixin Finance reported that the company was founded in March 2024 in Suzhou High-tech Zone and works on implantable bidirectional interfaces and neuromodulation, with in-house layers covering electrodes and sensors, chips and hardware, packaging, and data and algorithms.

## Two cases, two cases, and one 20-metre walk

Clinical progress is measured in investigator-initiated studies: two cases each in spinal cord injury paraplegia and post-stroke hemiplegia.

One patient with complete spinal cord injury walked more than 20 metres unaided one month after surgery.

In January 2026, the company completed Anhui's first implantable closed-loop brain-computer interface procedure, with upper-limb movement-intent decoding accuracy of at least 95%.

All three figures come from Zhixin Finance. The company has not itemized them in its own announcement, and no follow-up duration was disclosed.

## Four certificates, 80 people

The same report gives two more figures: four medical device registration certificates, an expected 2026 revenue in the tens of millions of yuan, and more than 80 employees.

A rough division follows. Nearly 100 million yuan spread across 80-plus people is about 1.2 million yuan per head. Revenue in the tens of millions across 80 people is a fraction of that per head.

The arithmetic is mine and the two data sets do not use identical scopes. But it locates the company: the money is R&D money, the revenue is product revenue, and the two lines have not crossed.

Of the four certificates, the ones supporting current revenue are mainly neuromuscular electrical stimulation products. The certificate that matters most is still in the clinic.

## Financing is not approval

The regulatory path for implantable devices is long: clinical research, type testing, clinical trials, review. Each stage is measured in years.

So this round buys clinical milestones, not a marketed product.

For primary investors, the logic in brain-computer interfaces shifted in the second half of 2026: from telling a technology story to reading clinical milestones.

What won this company a lead investor was four completed studies and one 20-metre walk.

## Why stimulation products come first

The revenue line deserves a closer look, because it explains the strategy.

Neuromuscular electrical stimulation devices are mature, reimbursable in some settings, and cheap to manufacture relative to implants. They give a young company a regulatory track record, a sales channel into rehabilitation departments, and cash flow that does not depend on a decade-long implant programme.

The implant programme is where the value sits, and where the timeline is longest. A four-certificate portfolio with one implant product in clinical research is a common shape in Chinese neurotech: commercial products fund the frontier, and the frontier is what investors price.

Reimbursement is the unstated question. An interface that restores walking is a clinical achievement; whether hospitals get paid for the procedure determines whether it becomes a product line. That answer comes after approval, not before.

## Why the timeline is measured in years

Regulators treat an implant that stimulates the spinal cord with the same caution as any other permanently implanted device. The sequence runs from investigator-initiated studies to type testing, then a pivotal trial, then review, and each stage can require redesign.

That is why the company describes its four completed cases as research rather than trials. Research establishes feasibility and generates the evidence a trial protocol needs. It does not shorten the trial.

What the money buys is the ability to run several indications in parallel: movement, language, vision, mood. Each indication needs its own protocol, its own ethics review and its own clinical sites, which is why nearly 100 million yuan is a start rather than a finish.

*Disclaimer: This article draws on reporting by Economic Observer and Zhixin Finance. Calculations are the author's own. It is for reference only and does not constitute investment advice.*

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-bsi-pre-a-1120
Free to quote with attribution and a link to the original.
